


IV-361

Cat. No.:	HY-139011		
CAS No.:	2055741-39-2		
Molecular Formula:	C ₂₃ H ₃₂ FN ₅ O ₂ Si		
Molecular Weight:	457.62		
Target:	CDK		
Pathway:	Cell Cycle/DNA Damage		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 90 mg/mL (196.67 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.1852 mL	10.9261 mL	21.8522 mL
		5 mM	0.4370 mL	2.1852 mL	4.3704 mL
10 mM		0.2185 mL	1.0926 mL	2.1852 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.25 mg/mL (4.92 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.25 mg/mL (4.92 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	IV-361 is an orally active and selective CDK7 inhibitor (K _i ≤50 nM). IV-361 has anti-cancer activity (US20190256531A1) ^[1] .	
IC₅₀ & Target	CDK7 ≤50 nM (Ki)	CDK2 ≥1000 nM (Ki)
In Vitro	IV-361 has less inhibition on CDK2 (K _i ≥1000 nM) or PLK1 (K _i ≥5000 nM) ^[1] . IV-361 exhibits excellent IL-2 and IL-17 production inhibitory activity (all IC ₅₀ ≤100 nM) in periphery blood mononuclear cell (PBMC) ^[1] . IV-361 exhibits excellent HCT-116 cell growth inhibitory activity (GI ₅₀ ≤100 nM) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

In Vivo

IV-361 (25 mg/kg/day; orally) exhibits 46% or more rate of suppression of tumor volume in female BALB nude mice with HCT-116^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Noriaki Iwase, et al. Substituted dihydropyrrolopyrazole derivative. US20190256531A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA